What question did this study set out to answer?

This study aims to evaluate the frequency and risk factors of hematologic immune-related adverse events in patients treated with immune checkpoint inhibitors.

December 8, 2025Blood

Real-world burden and risk analysis of hematologic iraes in patients treated with immune checkpoint inhibitors: 5-year cohort study

View Full Paper

Ask AI

Bookmark

This study aims to evaluate the frequency and risk factors of hematologic immune-related adverse events in patients treated with immune checkpoint inhibitors.
Retrospective cohort study at a tertiary cancer center
Included adult patients treated with ipilimumab, nivolumab, pembrolizumab, atezolizumab, or durvalumab
Reviewed electronic medical records for hematologic toxicities and demographics
Utilized binary logistic regressions to assess predictors of hematologic irAEs
62.9% of patients experienced at least one hematologic irAE after ICI treatment
Anemia was the most common irAE (44.8%), followed by thrombocytopenia (28.4%)
No grade 4 or 5 hematologic events were reported
Most hematologic irAEs were mild and resolved with supportive care
Early monitoring is crucial for managing hematologic irAEs effectively

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Cohort study reports frequent hematologic irAEs in melanoma and renal cancer patients receiving immunotherapy, indicating need for early detection.

Cite This Study

Ali Awada (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236dff8 https://doi.org/10.1182/blood-2025-4471

View Full Paper

Ask AI

Bookmark

Implication

Cohort study reports frequent hematologic irAEs in melanoma and renal cancer patients receiving immunotherapy, indicating need for early detection.

Real-world burden and risk analysis of hematologic iraes in patients treated with immune checkpoint inhibitors: 5-year cohort study

Key Points

Discussion

Implication

Cite This Study

Real-world burden and risk analysis of hematologic iraes in patients treated with immune checkpoint inhibitors: 5-year cohort study

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading